Administration of Off-label Drug Uses of Efgartigimod in the Treatment of Guillain-Barré Syndrome
10.3870/j.issn.1004-0781.2025.06.022
- VernacularTitle:艾加莫德治疗吉兰-巴雷综合征的超说明书用药管理
- Author:
Xiao JIANG
1
;
Liu TANG
;
Xuedan ZHENG
Author Information
1. 武汉大学人民医院药学部,武汉 430060
- Publication Type:Journal Article
- Keywords:
Efgartigimod;
Guillain-Barré syndrome;
Medication therapy management;
Off-label drug use
- From:
Herald of Medicine
2025;44(6):973-977
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze and intervene in typical cases of off-label drug uses of efgartigimod in the treatment of Guillain-Barré syndrome,and to provide further medication strategies for the management of Guillain-Barré syndrome.Methods By reviewing the treatment of two cases of Guillain-Barré syndrome,where intravenous immunoglobulin was ineffective or the blood product supply was limited,the clinical pharmacist conducted an evidence-based evaluation of the off-label drug uses of efgartigimod for the treatment of Guillain-Barré syndrome following guidelines and norms,provided assistance to the physician in developing a treatment regimen(10 mg·kg-1 once a week for 4 weeks),and closely monitored and evaluated the medication administration process.Results Two patients had significant improvement and no serious adverse events after treatment with efgartigimod.Clinical pharmacists play an important role in the decision-making,regulation and monitoring of off-label drug uses,ensuring the safety and rationality of medication use.Conclusion Clinical pharmacists should actively involved in the practice of off-label drug uses and make a contribution to the promotion of rational clinical use of medication.
